相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2022)
Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report
Arjunmohan Mohan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial
K. Goodwin et al.
Journal of Thoracic Oncology (2021)
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1b/2 trial of tepotinib in sorafenibpretreated advanced hepatocellular carcinoma with MET overexpression
Thomas Decaens et al.
BRITISH JOURNAL OF CANCER (2021)
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
Baek-Yeol Ryoo et al.
BRITISH JOURNAL OF CANCER (2021)
Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
P. Paik et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
M. C. C. Garassino et al.
ANNALS OF ONCOLOGY (2021)
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu et al.
LANCET RESPIRATORY MEDICINE (2021)
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
Wenyuan Xiong et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S. Falchook et al.
CLINICAL CANCER RESEARCH (2020)
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
M. A. Pruis et al.
LUNG CANCER (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
P. K. Paik et al.
ANNALS OF ONCOLOGY (2020)
Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 SkippingNon-SmallCell Lung Cancer
Xiuning Le et al.
ONCOLOGIST (2020)
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
Kohei Shitara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun et al.
BMC CANCER (2019)
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
Rubens Barros Costa et al.
Oncotarget (2018)
Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1
Saki Omote et al.
SCIENTIFIC REPORTS (2018)
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
Jordi Remon et al.
JOURNAL OF THORACIC DISEASE (2018)
Lung cancer and interstitial lung disease: a literature review
Jean-Marc Naccache et al.
JOURNAL OF THORACIC DISEASE (2018)
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
Kartik Sehgal et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Drug-Induced Interstitial Lung Disease: A Systematic Review
Sarah Skeoch et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Renal function monitoring in heart failure - what is the optimal frequency? A narrative review
Ahmed Al-Naher et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Pei Ni Ding et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
DRUG SAFETY (2016)
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Antonio Rossi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation
Tom T. Chen et al.
EBIOMEDICINE (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development
Stephen P. Hack et al.
ONCOTARGET (2014)
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
GV Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
